Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis by Matta, Bassem et al.
Worldwide Variations in Demographics, Management, and Outcomes of 
Acute Pancreatitis  
Bassem Matta1, Amir Gougol2, Xiaotian Gao3, Nageshwar Reddy4, Rupiyoti Talukdar5, Rakesh Kochhar6, 
Mahesh Kumar Goenka7, Aiste Gulla8, Jose A. Gonzalez9, Vikesh K. Singh10, Miguel Ferreira11, Tyler 
Stevens12, Sorin T. Barbu13, Haq Nawaz14, Silvia C. Gutierrez15, Narcis O. Zarnescu16, Gabriele 
Capurso17, Jeffrey Easler18, Konstantinos Triantafyllou19, Mario Pelaez-Luna20, Shyam Thakkar21, Carlos 
Ocampo22, Enrique de-Madaria23, Gregory A. Cote24, Bechien U. Wu25, Pedram Paragomi26, Ioannis 
Pothoulakis27, Gong Tang28, & Georgios I. Papachristou29,30  
1, Bassem Matta: matta.bassem@gmail.com 
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
2, Amir Gougol: gougolah@upmc.edu 
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
1 and 2 contributed equally as first authors 
3, Xiaotian Gao: XIG31@pitt.edu 
Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 
4. Nageshwar Reddy: aigindia@yahoo.co.in
Asian Gastroenterology Institute, Hyderabad, India 
5, Rupiyoti Talukdar: rup_talukdar@yahoo.com 
Asian Gastroenterology Institute, Hyderabad, India 
6, Rakesh Kochhar: dr_kochhar@hotmail.com 
Postgraduate Institute of Medical Education and Research, Chandigarh, India 
7, Mahesh Kumar Goenka:  mkgkolkata@gmail.com 
Apollo Gleneagles Hospitals Kolkata, Kolkata, India  
8 Aiste Gulla: agulla1@jhu.edu 
Lithuanian University of Health Sciences, Kaunas, Lithuania 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Matta, B., Gougol, A., Gao, X., Reddy, N., Talukdar, R., Kochhar, R., … Papachristou, G. I. (2019). Worldwide Variations in 
Demographics, Management, and Outcomes of Acute Pancreatitis. Clinical Gastroenterology and Hepatology. 
https://doi.org/10.1016/j.cgh.2019.11.017
2
9, Jose A. Gonzalez: joseagonz@yahoo.com 
Universidad Autónoma de Nueva León, Monterrey, Mexico 
10, Vikesh Singh, vsingh1@jhmi.edu 
Johns Hopkins Medical Institutions, Baltimore, Maryland, USA 
11, Miguel Ferreira: migue.ferbo@hotmail.com 
Hospital Nacional de Itauguá, Itaugua, Paraguay 
12, Tyler Stevens: STEVENT@ccf.org 
Cleveland Clinic Foundation, Cleveland, Ohio, USA 
13, Sorin T. Barbu: barbu@pancreasclub.ro 
University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania; 
14, Haq Nawaz: hnawaz@emhs.org 
Eastern Maine Medical Center, Maine, Bangor, USA 
15, Silvia C. Gutierrez: silviac.gutierrez@gmail.com 
Hospital Nacional "Profesor Alejandro Posadas", Buenos Aires, Argentina 
16, Narcis O. Zarnescu: nzarnescu@gmail.com 
University of Medicine and Pharmacy, Bucharest, Romania 
17, Gabriele Capurso: capurso.gabriele@hsr.it 
San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy 
18, Jefferey Easler: jjeasler@iu.edu 
Indiana University School of Medicine, Indianapolis, Indiana, USA 
19, Konstantinos Triantafyllou: chronisgatos@gmail.com 
Attikon University General Hospital, Athens, Greece 
3
20, Mario Pelaez-Luna: mariopl@prodigy.net.mx  
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán-Universidad Autónoma de Mexico, 
Mexico City, Mexico 
21, Shyam Thakhar: sthakkar@wpahs.org  
Allegheny General Hospital, Pittsburgh, Pennsylvania, USA 
22, Carlos Ocampo: ocampoc@yahoo.com 
Hospital General de Argudos "Dr. Cosme Argerich", Buenos Aires, Argentina 
23, Enrique De-Madaria: madaria@hotmail.com 
Investigación Sanitaria y Biomédica de Alicante (ISABIAL - Fundación FISABIO), Alicante, Spain 
24, Gregory A. Cote: cotea@musc.edu 
Medical University of South Carolina, Charleston, South Carolina, USA
25, Bechien Wu: Bechien.U.Wu@kp.org 
Kaiser Permanente, Pasadena, California, USA 
26, Pedram Paragomi: paragomi@pitt.edu 
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
27, Ioannis Pothoulakis, gianhspoth1@gmail.com 
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
28, Gong Tang, got1@pitt.edu 
Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, 
USA 
29, 30 Georgios Papachristou: papachri@pitt.edu  
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Ohio State University Wexner Medical Center, Columbus, Ohio, USA 
4
Short Title: Geographic Variations in Acute Pancreatitis 
Corresponding author: Georgios Papachristou, MD, PhD 
Title: Professor of Medicine at the Ohio State University Wexner Medical Center, Columbus, 
OH. 
Email: georgios.papachristou@osumc.edu 
Telephone number: +1 (614) 293-6255  
Fax number: +1 (614) 293-8518 
Office: 410 W 10th Avenue, 2nd floor, Columbus OH, 43210 
None of the authors have published, posted, or submitted any related papers from the same study.
5
Acknowledgments: 
• Ayesha Kamal, M.D.
• Benjamin Click, M.D.
• David Whitcomb, M.D., PhD.
• Dhiraj Yadav, M.D., MPH.
• Efstratios Koutroumpakis, M.D.
• Peter Jun Woo Lee, MBChB.
• Phil J Greer, M.S.
• Venkata, Akhintala, M.D.
Author contributions:
• Statistical analysis: Xiaotian Gao and Gong Tang.
• Drafting of the manuscript: Bassem Matta, Amir Gougol, and Georgios I. Papachristou.
• Data collection, data interpretation, review of manuscript for important intellectual
content, final approval of the manuscript: all authors
Conflict of interest and financial disclosures: 
None of the authors have any conflict of interest or pertinent financial disclosures.
6
Abbreviations: 
AGA: American gastroenterological association 
AP: acute pancreatitis 
APPRENTICE: acute pancreatitis patient registry to examine novel therapies in clinical 
experience 
BMI: body mass index 
CI: confidence interval 
DUA: data use agreements 
ERCP: endoscopic retrograde cholangiopancreatography 
ICU: intensive care unit 
IQR: interquartile range 
IRB: institutional review board 
RAC: revised Atlanta classification 
REDCap: Research Electronic Data Capture  
LOS: length of stay 
SIRS: systemic inflammatory response syndrome  
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Abstract:  
Background & Aims: Few studies have compared regional differences in acute pancreatitis. We 
analyzed data from an international registry of patients with acute pancreatitis to evaluate 
geographic variations in patient characteristics, management, and outcomes. 
Methods: We collected data from the APPRENTICE registry of patients with acute pancreatitis, 
which obtains information from patients in Europe (6 centers), India (3 centers), Latin America 
(5 centers), and North America (8 centers) using standardized questionnaires. Our final analysis 
included 1,612 patients with acute pancreatitis (median age, 49 years; 53% male, 62% white) 
enrolled from August 2015 through January 2018.  
Results: Biliary (45%) and alcoholic acute pancreatitis (21%) were the most common etiologies. 
Based on the revised Atlanta classification, 65% of patients developed mild disease, 23% 
moderate, and 12% severe. The mean age of patients in Europe (58 years) was older than mean 
age for all 4 regions (46 years) and a higher proportion of patients in Europe had comorbid 
conditions (73% vs 50% overall). The predominant etiology of acute pancreatitis in Latin 
America was biliary (78%), whereas alcohol-associated pancreatitis accounted for the highest 
proportion of acute pancreatitis cases in India (45%). Pain was managed with opioid analgesics 
in 93% of patients in North America versus 27% of patients in the other 3 regions. 
Cholecystectomies were performed at the time of hospital admission for most patients in Latin 
America (60% vs 15% overall). A higher proportion of European patients with severe acute 




Conclusions: We found significant variation in demographics, etiologies, management practices, 
and outcomes of acute pancreatitis worldwide. 
 
ClinicalTrials.gov number: NCT03075618 
 
















Acute pancreatitis (AP) is a global leading cause of gastrointestinal-related hospital admissions 1. 
The incidence of AP has been reported to be increasing in the United States and Europe 2, 3. 
Approximately 20% of people affected develop severe disease resulting in relatively high 
morbidity and mortality 4. Over the last decade, multiple advances have occurred in management 
of AP such as the development of the revised Atlanta classification of disease severity (RAC), 
introduction of early goal-directed intravenous fluid resuscitation, and implementation of a 
minimally invasive step-up approach in subjects with symptomatic necrotic pancreatic 
collections 5-7. Possibly as a consequence of these developments, case fatality of AP may have 
decreased however, estimates tend to vary among different countries 8, 9. 
Large, multicenter studies in AP from national registries have been recently published. However, 
these have been confined to national bounds, with the majority being in North America and 
Europe 10-13. Results from these studies have revealed heterogeneity in patient characteristics 
such as demographics, etiology, and risk factors of severe disease. For instance, a large Spanish 
study from 2018 revealed an AP mortality rate of 4.2% compared to 1% from recent reports in 
the United States 13, 14. Inconsistent severity definitions and methodology hinder the combination 
and comparison of data from different regions. Furthermore, it is unclear whether recent 
advances in management of AP have gained traction throughout different areas of the world.  
Lack of prospective, multi-national data in AP prompted investigators around the world to create 
a multi-center collaboration referred as Acute Pancreatitis Patient Registry to Examine Novel 
Therapies in Clinical Experience (APPRENTICE)15. This study’s aim was to evaluate the 
geographic differences in patient characteristics, management, and outcomes of AP across four 




APPRENTICE is a prospective, multicenter, international consortium studying clinical 
characteristics of AP patients across the world15. The University of Pittsburgh served as the 
coordinating center. Ethical committee approvals were obtained from local institutional review 
boards (IRB) at all participating centers. University of Pittsburgh’s IRB approved this study and 
acted as an umbrella IRB for incoming centers (PRO15040389). The study was registered in 
clinicaltrials.gov (NCT03075618). Details on design and methodology of APPRENTICE have 
been previously published15. Adults (≥18 years old) admitted with the diagnosis of AP, willing to 
participate in the study, and enrolled within 2 weeks of presentation were eligible for inclusion. 
Patients with a history of organ transplantation, trauma induced AP, chronic pancreatitis, and 
pancreatic cancer were excluded. Enrollment occurred between October 2015 and January 2018. 
Site investigators were responsible for identifying eli ible hospital admitted patients through 
different screening mechanisms. In total, data from 22 sites, which reached a set minimum 




Study questionnaires were carefully designed by recognized experts in the field (appendix table 
1). A well-established, secure, web-based, electronic data collection software (Research 
Electronic Data Capture, REDCap) was used16. A test period of 3 months was initially 
undertaken with the goal to assess applicability and quality of the questionnaires. Multiple online 
sessions with study personnel (site investigators, coordinators) were conducted prior to, and 
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during the enrollment phase in order to ensure the uniformity of data collection, answer 
questions, and address technical issues. De-identified data was collected prospectively at 
different hospitalization time points: admission, day 1, day 2, day 3, day 7, and discharge. Data 
quality was routinely monitored by a dedicated stati ician at the coordinating site. Definition of 
different collected variables are outlined in appendix table 2.  
The primary clinical outcomes of interest included RAC severity, LOS, and in-hospital mortality. 
Additional outcomes included AP etiology, fluid volume in the first 24 hours of admission, fluid 
type, analgesic use, feeding methods, and ERCP, or cholecystectomy rates in cases of biliary 




Statistical analysis was performed by expert biostatisticians (X.G., G.T.) at the coordinating 
center. Continuous variables were summarized by median and interquartile range (IQR). 
Categorical variables were presented with proportions f study subjects. Preliminary 
comparisons of outcome variables among various geographic areas, were performed using the 
Fisher’s exact test for categorical values, and the nonparametric Kruskal-Wallis test was used for 
continuous variables (Tables 2-5). These were used a  global tests that compared patient 
characteristic and clinical outcomes of interest through all four regions. Significance was defined 
as a p-value equal to or less than 0.05; no adjustment for multiple testing was made in these 
exploratory analyses.  
Subsequently, we focused on the primary clinical outc mes and multivariate regression models 
were applied to assess whether LOS, severity, and mortality differ among the four geographic 
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areas, adjusting for other patient characteristics. The geographic regions were coded by three 
dummy variables, with North America as the reference region. For multivariable analysis, a 
linear regression was used to evaluate LOS differences among geographic areas, and logistic 
regression was used to assess differences in severity (severe AP vs. others) and mortality (severe 
patients) among different regions. Such differences in outcomes between a region (Europe, India, 
or Latin America) and North America were presented as odds ratios in the case of severity and 
mortality, or as associated model coefficients in the case of LOS (Appendix Tables 3-5).  
Multivariable models were run including the following covariates: age, gender, body mass index 
(BMI), Charlson Comorbidity Index, etiology, transfer status, cholecystectomy during the same 
admission, narcotic use, and severity (only for LOS).  The covariates of age, BMI, Charlson 
Comorbidity Index, and etiology were constantly kept in the model for more accurate prediction, 
while the remaining covariates dropped when not significant. The likelihood ratio test was used 
to compare the nested model with region and the adjusted variables as covariates and the sub-
model with only the adjusted variables as covariates. All analyses were performed in R (Version 
3.5.1, R Foundation). 
Study participants: 
In total, 1,680 AP patients were enrolled between August 2015 and January 2018; 68 were 
omitted from the analysis yielding a final number of 1,612 subjects. Exclusion of the above 
subjects was related to removal of sites with <15 subjects enrolled from the analysis (13 
patients), as part of the predetermined study criteria, or due to missing RAC data (55 patients; 
Table 1, Figure 1). 
Results 
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Baseline Characteristics and Etiology 
Out of the 1,612 patients, median age was 49 (IQR, 34-64), and 47% were females. Biliary 
(45%) and alcoholic (21%) were the most common pancreatitis etiologies (Table 2). Based on 
RAC, 65% were classified as developing mild disease, 23% as moderately severe, and 12% as 
severe disease. Median LOS was 8 days (IQR, 5-13, Table 4). Overall, 45 patients died (2.8%) 
during their hospitalization (Table 5).  
Age, gender, ethnicity, and race distributions differed significantly by geographic areas. Patients 
from Indian sites were mostly males (75%), younger in age (39 years, IQR: 30-50) with alcohol 
being the predominant etiology (45% vs. 14% in remaining geographic areas, p <0.001). Latin 
American patients were mostly young (median age 43, IQR 29-59), females (67%) with the 
majority of AP linked to biliary etiology (78% vs. 37%, p<0.001). In contrast, European and 
North American subjects had a relatively equal gender distribution, with an overall older age [58, 
(IQR 45-74) and 52 (IQR 37-65) respectively, p <0.001]. Post ERCP pancreatitis was 
significantly more common in North American sites (19% vs 2.8% in remaining geographic 
areas, p<0.001) (Table 2). These differences were mostly driven by two North American sites 
with 50 out of 90 and 22 out of 62 enrolled patients classified as post ERCP pancreatitis, 
respectively.  
Management 
Data on patient management is presented in table 3. The amount of intravenous fluids 
administered over the first 24 hours was relatively similar between India, Latin America and 
North America (ranged between 3-3.2 liters); however, was significantly lower in Europe (2.5 
liters, p<0.001). Lactated Ringers (LR) and normal saline were the two main types of 
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intravenous fluids administered in all regions except Latin America.  LR was the dominant type 
of fluid in India (92%) in contrast to Latin America, where it was rarely used (7%, p <0.001).  
The major types of fluids given in Latin America were normal saline (61%) and Hartman’s 
(32%); a balanced solution similar to LR, which is not widely available in this region.  
The utilization of analgesics was markedly variable across the world. In Europe, non-steroidal 
anti-inflammatory medications (NSAIDs) comprised the mainstay of pain management (68%). 
Indian sites, however, used tramadol in 91% of their patients, while Latin American centers 
frequently used opioids (59%), NSAIDs (48%), and tramadol (34%). In contrast, opioid 
analgesics constituted the cornerstone of analgesia in North America at 93% of subjects in 
contrast to 27%  in the remaining regions (p<0.001). Furthermore, 64% of subjects in North 
America were discharged on opioid analgesics compared to 2.7% in other geographic areas 
(p<0.001).  
European centers had the highest ratio of enteral to parenteral nutrition at 10:1 (32% vs. 3% in 
subjects with moderate or severe disease); whereas, tot l parenteral nutrition (TPN) was most 
commonly administered in India in 27% of patients compared to 20% receiving enteral nutrition 
(ratio <1:1).  The frequency of ERCP among subjects with biliary AP was significantly higher in 
North America (45% vs. 14% for the remaining sites, p<0.001). With respect to same admission 
cholecystectomy, considerable variations were noted among patients with mild acute biliary 
pancreatitis; it was performed in 60% of such patients in Latin America, while in only 15% in 
India (p<0.001). Moreover, early pancreatic interventions among patients with moderate or 




When comparing the LOS among mild AP, patients in North America were found to stay in the 
hospital the shortest time (4 days) compared to other regions (7 days; p<0.001). Severe AP 
developed in 23% of Indian patients compared to 9% in the rest of world (p<0.001, Table 4). 
ICU admissions were highest in Indian centers at 37.9% (Table 5). In-hospital mortality was 
found to be the highest in Europe (5.7%), followed by India (3.3%), Latin America (2.3%), and 
North America (0.6%, p<0.001, Table 5). Among European sites included, in hospital mortality 
in different countries was distributed as such; Greece: 0%, Spain: 5%, Lithuania: 6.4%, and 
Romania: 8.6%.   
Multivariate Analysis of outcomes: 
Based on multivariable  regression analyses that adjusted for potential confounders such as age, 
gender, BMI, Charlson score, etiology, transfer status, and other factors, the odds of severe AP 
were 11.2 times higher in Europe [95% confidence int rval (CI): 5.8-21.6], 7 times higher in 
India (CI: 3.8-12.8), and 5.6 times higher in Latin America (CI: 2.8-11.1), compared to North 
America (p<0.001, Appendix Table 3). LOS was 4.3 days longer (CI: 3.5-5.4) in Europe, 1.1 
days longer (CI: -0.1-2.3) in India, and 6.4 days longer (CI: 5.2-7.7) in Latin America when 
compared to North America (p<0.001, Appendix Table 4). The ORs for same-admission 
mortality among severe AP patients was 10.4 (CI: 2.7-40.5) in Europe, 4.2 (CI: 0.9-18.8) in 
India, and 8.3 (CI: 1.7-41.3) in Latin America when compared to North America (p<0.001, 
Appendix Table 5).  
Discussion  
In this large prospectively collected registry, significant differences in AP patient demographics, 
etiology, management approaches, severity and clinica  outcomes were seen around the world.  
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Observed differences in etiology and demographics likely reflect a tight interconnection between 
age, gender, and etiology. In Indian sites, where the most preponderant AP etiology was alcohol, 
the majority of patients were young males. Previous studies have revealed a high proclivity of 
alcoholic pancreatitis in young Indian adults with heavy drinking patterns 2, 17-19. More 
specifically, a recent study from India published in 2018 reported an average age of 40 years 
with alcoholic pancreatitis representing 42% of all etiologies 20.  In Latin American sites, females 
were the predominant gender with biliary etiology being the most common. Latin America is 
known to have the highest rate of gallstone disease (more common among women) compared to 
other parts of the world 21, 22. A study in 2015 emanating from Argentina revealed similar 
findings, with biliary etiology accounting for 88% of all causes, and 58% of subjects being 
females12. Along the same lines, older age among subjects from Europe is congruent with a study 
published in 2018 from this region13.    
With regards to AP management, discrepancies in intravenous fluid volume and type 
administered over the first 24 hours are likely related to differences in accessibility to certain 
types of fluids, but most importantly, lack of high quality evidence supporting which type and 
what amount of fluid is optimal, as highlighted in the recent American Gastroenterological 
Association (AGA) guidelines in 2018 23-27. Our findings further support the need for adequately 
powered, multi-center, randomized controlled trials comparing the efficacy of different fluid 
resuscitation protocols in AP patients. 
The finding of disproportionally higher rate of opioid prescription during hospitalization and at 
the time of discharge in the North American sites is alarming. Of interest, a meta-analysis 
comparing NSAIDs versus opioids for pain control in AP subjects revealed no difference in the 
efficacy between the two treatments 28, 29. It not entirely clear why such divergences exist 
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between North American centers compared to the rest of the world. Notably, no clear statements 
are included in the current societal guidelines addressing optimal strategies for analgesia in AP. 
Based on strong evidence, current guidelines recommend limited utilization of urgent ERCP only 
among biliary AP patients with suspicion of cholangitis or biliary obstruction23. Our study 
showed that the rate of ERCPs performed in patients with biliary AP was much higher in North 
American sites. Impressive discrepancies have been previously reported in different counties, i.e.  
81% in Hungary, 52% in the United States, and 9% in Argentina 10-12. The discrepancies 
observed in our study are difficult to explain; they are possibly related to referral bias, local 
practice patterns, as well as compensation structure differences . 
Recent evidence supports same admission cholecystectomy among patients with biliary AP 23, 24.
Our study revealed that the rate of same admission cholecystectomy varied significantly with the 
highest seen in Latin America and lowest in India. Upon further discussion with site 
investigators, it appears that AP patients are traditionally admitted under surgical care in Latin 
America, making performance of inpatient cholecystectomy logistically easier. A recent 
publication from Latin America confirmed these findings, where 54% of biliary AP subjects 
underwent same admission cholecystectomy12. In contrast, the low rate of same admission 
cholecystectomy in India could be explained by the high rate of transfers in the participating sites 
combined with patient preference to undergo this relatively simple operation locally at a later 
time. 
Robust evidence highlights the use of enteral nutrition over TPN, and delaying pancreatic 
interventions in patients with moderate and severe AP, which is endorsed by current practice 
guidelines 23 5, 30, 31. These recommendations were least adhered to in Indian centers, which is 
possibly accentuated by the higher rate of transfers.   
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It is clear from the management practices seen in our study that the adherence to current 
evidence-driven societal guidelines varies significantly between different geographic regions of 
the world. Only a minority of the above practice patterns could be explained based on 
availability of resources. Thus, certain aspects of AP management such as the excessive 
administration of opioid analgesics and performance of ERCP in North American centers, 
overuse of TPN, and early pancreatic interventions n Indian sites, appear to lag behind the 
evidence.  Additional effort is clearly needed to augment clinical implementation of certain 
therapeutic approaches supported by strong evidence in AP. 
The finding that mild AP patients in North American centers had a shorter LOS compared to 
other regions is consistent with a recent report showing that the overall LOS of AP in the U.S. 
has decreased from 6.5 days in 1997 to 4.7 in 2015 1. This is likely related to incentive policies 
that have been applied over the last two decades in the U.S. resulting in shortening inpatient 
admissions32.   
Our study revealed higher death rate among European sites when compared to other geographic 
regions. . This observation could potentially be related to older age and higher rate of comorbid 
conditions seen in the European centers, both of which have been linked to mortality 33. Notably, 
this difference persisted after adjustment for pertin nt covariates in our multivariate analysis 
raising the question of other contributing factors. The lower mortality rate in North America 
seems consistent with recent reports indicating a decreased mortality over the last decade in the 
U.S, possibly related to improved quality of ICU care, and optimal timing for interventions 14, 34. 
Factors pertaining to baseline health and socioeconomic factors could possibly have contributed 
to these dispcrepancies in mortality. 
19
This study, has several strengths. It is the first of its kind to characterize differences in 
demographics, etiology, clinical profile, and management patterns and clinical outcomes in AP, 
by giving a snapshot of subject characteristics across different geographical regions of the world. 
Prior studies tackling this topic were limited by national bounds and lack of standardized 
methods for data acquisition.  Distinctive attributes, which contribute to this study’s strength, 
include its prospective nature, the large sample size with balanced representation between the 
different geographic areas with inclusion of at least 300 subjects from each studied region. 
Another important feature is the relatively recent time of data acquisition over the last 3 years, 
following the introduction of the RAC thus, accurately reflecting current practices 7, 24. 
Moreover, most included sites were large, reputable institutions, with a high degree of expertise 
relating to pancreatic diseases. Furthermore, data collection was standardized, under rigorous 
monitoring resulting in a high data completeness rate, and quality. Finally, at the conclusion of 
the data collection process, in an attempt to better understand regional practice patterns, an 
additional step was undertaken in obtaining site investigators’ input into explaining the observed 
results. 
With regards to the study’s limitations, certain parts of the world such as Africa, the Middle East, 
or East Asia, were not represented.  Moreover, the majority of participating sites were academic 
tertiary care hospitals, which may introduce a bias potentially affecting the generalizability of 
our results. Especially in North America, major  ERCP referral centers were included whose 
unusual practice mix may not reflect that of the typical large American hospital. Fin lly, the 
proportion of subjects enrolled in the study compared to all AP patients hospitalized at each site, 
varied based on available research resources. 
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In conclusion, we present a bird’s eye view of the variations in clinical characteristics of AP 
patients across the world by using a large, prospective, international registry. There appears to be 
remarkable variations in frequency of AP etiologies in different regions. The therapeutic 
interventions specific to each region are in certain aspects strikingly divergent, and in many 
occasions lag behind current evidence. Outcomes, such as LOS and mortality, are largely 
variable. In addition to depicting key features of AP, the results from this study may serve as a 
reference guide for designing future clinical trials. 
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# of Beds 





LUHS, Kaunas, Lithuania Europe 109 >1000 100-200 50-75% 
University of Medicine, Cluj-Napoca, Europe 82 101-200 50-100 25-50% 
University of Medicine, Bucharest, Romania Europe 70 >1000 100-200 <25% 
Sapienza University, Rome, Italy Europe 69 301-500 50-100 <25% 
Attikon University, Athens, Greece Europe 59 501-750 50-100 <25% 
Investigación, Alicante, Spain Europe 20 751-1000 100-200 <25% 
AIG, Hyderabad, India India 136 201-300 200-300 >75% 
Postgraduate Institute, Chandigarh, India India 119 >1000 300-500 50-75% 
Apollo Gleneagles, Kolkata, India India 111 501-750 50-100 <25% 
UAN, Monterrey, Mexico Latin 95 301-500 100-200 <25% 
Hospital Nacional, Itaugua, Paraguay Latin 83 301-500 100-200 <25% 
Nacional “Posadas”, Buenos Aires, Argentina Latin 71 301-500 100-200 <25% 
Universidad Autónoma, Mexico City, Mexico Latin 47 201-300 50-100 25-50% 
Hospital de Argudos, Buenos Aires, Argentina Latin 29 301-500 50-100 25-50% 
UPMC, Pittsburgh, USA North 130 751-1000 100-200 50-75% 
Johns Hopkins, Baltimore, USA North 90 >1000 100-200 25-50% 
Cleveland Clinic, Cleveland, USA North 82 >1000 >500 25-50% 
EMMC, Bangor, USA North 81 301-500 100-200 25-50% 
Indiana University, Indianapolis, USA North 62 201-300 200-300 50-75% 
AGH, Pittsburgh, USA  North 32 501-750 300-500 25-50% 
MUSC, Charleston, USA North 18 751-1000 200-300 50-75% 
Kaiser, Los Angeles, USA  North 17 301-500 100-200 <25% 
AP: acute pancreatitis, LUHS: Lithuanian University of Health Sciences, AIG: Asian Institute of Gastroenterology, 
UPMC: University of Pittsburgh Medical Center, UAN: Universidad Autónoma de Nueva , EMMC: Eastern Maine 
Medical Center. 
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Age, Median (IQR) 58 (45-74) 39 (30-50) 43 (29-59) 52 (37- 65) 49 (34-64) <0.001 
Gender, Male (%) 203 (49.6) 274 (74.9) 108 (33.5) 258 (50.6) 843 (52.5) <0.001 
Ethnicity, Hispanic or 
Latino (%) 
3 (0.7) 0 (0.0) 303 (97.4) 20 (4.0) 326 (20.6) <0.001 
Race (not Hispanic) 
- Asian Indian (%) 2 (0.5) 361(99.2) 0 (0.0) 6 (1.2) 36 (29.3) <0.001 
- Black or African -
American (%)
0 (0.0) 0 (0.0) 0 (0.0) 82 (16.9) 82 (6.5) 
- White (%) 397 (99.3) 0 (0.0) 8 (100.0) 386 (79.4) 791 (62.9) 
- Others (%) 1 (0.3) 3 (0.8) 0 (0.0) 12 (2.5) 16 (1.3) 
CCI  >1 (%) 298 (72.9) 132 (36.1) 153 (47.1) 314 (61.3) 897 (55.6) <0.001 
Obesity, BMI ≥ 30 (%) 111 (28.5) 27 (7.4) 86 (27.0) 220 (43.3) 444 (28.0) <0.001 
Etiology 
- Biliary (%) 206 (50.4) 102 (27.9) 249 (78.1) 170 (33.3) 727 (45.3) <0.001 
- Alcohol (%) 78 (19.1) 163 (44.5) 6 (1.9) 89 (17.5) 336 (20.9) 
- Idiopathic (%) 74 (18.1) 77 (21.0) 22 (6.9) 92 (18.0) 265 (16.5) 
- Hypertriglyceride
mia (%)
19 (4.6) 7 (1.9) 19 (6.0) 30 (5.9) 75 (4.7) 
- Post-ERCP (%) 13 (3.2) 8 (2.2) 15 (4.7) 97 (19.0) 133 (8.3) 
- Other (%) 19 (4.6) 9 (2.5) 8 (2.5) 32 (6.3) 68 (4.2) 
Current smoking 103 (26.1) 95 (26.0) 38 (11.9) 129 (25.3) 365 (23.0) <0.001 
Current alcohol use 194 (49.1) 166 (45.4) 57 (17.9) 189 (37.1) 606 (38.1) <0.001 
Recurrent AP 95 (23.2) 75 (20.5) 42 (13.2) 185 (36.3) 397 (24.8) <0.001 
Transfers (%) 81 (19.8) 260 (71.0) 35 (11.0) 171 (33.5) 547 (34.1) <0.001 
AP: acute pancreatitis, IQR: inter-quartile range, CCI: charlson comorbidity index, BMI: Body mass index. P 
values were calculated based on Fisher’s exact for categorical variables and Kruskal-Wallis global tests for 
continuous variables. Overall data completion rate was more than 95% for each of the variables
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Intravenous fluids  
      -       Amount, median 
(IQR)* 




3.0 (2.0-4.0) <0.001 
- Type of fluid, LR 
(%) 
315 (77.0) 337 (92.3) 24 (7.4) 253 (49.4) 930 (57.7) <0.001 
Inpatient pain management  
- NSAIDs (%) 277 (67.7) 1 (0.3) 155 (47.7) 91 (17.8) 524 (32.5) <0.001 
- Tramadol (%) 184 (45.0) 334 (91.3) 111 (34.2) 40 (7.8) 669 (41.5) <0.001 
- Opioids (%) 41 (11.9) 90 (24.9) 167 (59.0) 454 (92.5) 752 (50.8) <0.001 
Opioids at discharge (%) 1 (0.3) 2 (0.6) 17 (6.2) 314 (64.3) 334 (23.3) <0.001 
Nutritional support  
- Enteral Nutrition 
(%)** 
34 (31.8) 43 (19.9) 15 (15.3) 46 (34.8) 138 (25.0) <0.001 
- TPN (%)** 3 (2.8) 59 (27.3) 4 (4.1) 9 (6.8) 75 (13.6) <0.001 
ERCP (%)¥ 29 (14.4) 17 (16.8) 34 (14.1) 76 (44.7) 156 (21.9) <0.001 
Cholecystectomy (%)‡ 52 (31.7) 6 (15.0) 101 (59.8) 52 (42.6) 211 (42.6) <0.001 
Early pancreatic intervention 
(%)** 
9 (8.4) 50 (23.1) 5 (5.1) 9 (6.8) 73 (13.2) <0.001 
LR: Lactated ringers; NSAIDs: Non steroidal Anti-Inflammatory Drugs. P values are based on Fisher’s exact for 
categorical variables and Kruskall-Wallis global tes s for continuous one.  * Amount in liters within initial 24 hours 
of admission. ** Among RAC moderately severe or severe patients. ¥ Among Biliary AP patients. ‡ Among RAC 
mild biliary AP patients.  
Missing data: Narcotics use during hospitalization was missing in 65 patients in Europe, 4 in India, 23 in Latin 
America and 21 subjects in North America. Overall dta completion rate for narcotics during hospitaliztion was 
91.8%.  
Narcotics at discharge were missing in 90 patients i  Europe, 16 in India, 51 in Latin America and 24 subjects in 
North America. The overall data completion rate for Narcotics at discharge was 88.8% ; all other variables had 
overall data completion rate of over 95%.
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Table 4: Comparison of AP severity in various regions of the world. 













-Mild (%) 296 (73.4) 148 (40.7) 213 (68.5) 374 (73.9) 1031 (65.1) <0.001 
 
 
-Mod. severe (%) 59 (14.6) 134 (36.8) 75 (24.1) 94 (18.6) 362 (22.9) 
-Severe (%) 48 (11.9) 82 (22.5) 23 (7.4) 38 (7.5) 191 (12.1) 
RAC: revised Atlanta classification. Data completion rate is more than 95%. 



















Table 5: Comparison of AP LOS, ICU admissions, and in hospital mortality among various 
regions within each RAC group and among all study participants. 
LOS 












-Mild AP, median (IQR) 7 (6-10) 7 (5-9) 10 (6-16) 4 (3-6) 6 (4- 10) <0.001* 
-Mod. severe, median (IQR) 11 (8.5-18) 10 (7- 15) 17 (8.-26) 8.0 (6-12.8) 11 (7- 16) <0.001* 
-Severe, median (IQR) 28 (25- 41) 19 (13-25) 19 (13-25) 20 (13.5-32.5) 20 (14- 31) <0.001* 
-Overall, median (IQR) 8 (6-12) 9 (6- 15) 11 (7-19) 5 (3-8) 8 (5-13) <0.001** 
ICU Admissions 











-Mild AP (%) 2 (0.7) 18 (12.2) 0 (0.0) 9 (2.4) 29 (2.8) <0.001¥ 
-Mod. severe (%) 11 (18.6) 54 (40.3) 3 (4.0) 26 (27.7) 93 (25.8) <0.001¥ 
-Severe AP (%) 39 (81.2) 66 (80.5) 10 (43.5) 33 (86.8) 148 (77.5) <0.001¥ 
-Overall (%) 54 (13.3) 138 (37.9) 13 (4.2) 68 (13.4) 273 (17.2) <0.001¥¥ 
In Hospital Morality 













-Mild AP (%) 0 (0.0) 0 (0.0) 0(0.0) 0 (0.0) 0 (0.0) NA 
-Mod. severe (%) 2 (3.4) 1 (0.8) 0 (0.0) 0 (0.0) 3 (0.8) 0.12¶ 
-Severe AP (%) 21 (43.8) 11 (13.4) 7 (30.4) 3 (7.9) 42 (28.2) <0.001¶ 
-Overall (%) 23 (5.7) 12 (3.3) 7 (2.3) 3 (0.6) 45 (2.8) <0.001¶¶ 
LOS: length of stay. Mod. severe: moderately severe; ICU: intensive care unit; RAC: revised Atlanta crite ia. Data 
completion rate is more than 95%. 
* Kruskal-Wallis test was used to assess the associati n between regions and LOS within different severity groups. 
* * Kruskal-Wallis test was also applied for the association between regions and LOS among all participants. 
¥ Fisher’s exact test was used to assess the association between regions and ICU admissions within different 
severity groups. 
¥¥ Fisher’s exact test was also applied for the association between regions and ICU admissions among all study 
participants. 
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¶ Fisher’s exact test was used to assess the association between region and mortality (assessed in moderately severe 
and severe groups; no death seen in mild AP group) 






























Appendix Table 1. Study questionnaire. 
 


























Appendix table 2: Definitions of collected variables. 
Variable Definition 
AP diagnosis At least 2 out 3 three criteria:  
1) upper abdominal pain characteristic of AP  
2) serum amylase and/or lipase > 3 times the upper limit of normal 
3) imaging findings characteristic of AP 
Current smoking Active smoking within 6 months prior to admission 
Current alcohol use AP preceded by heavy alcohol consumption as determined by site investigators 
Alcoholic AP AP preceded by heavy alcohol consumption as determined by site investigators 
Biliary AP AP with objective evidence of cholelithiasis or choledocholithiasis on imaging, and 
no other plausible explanation for pancreatitis as determined by site investigators 
Hypertriglyceridemia 
induced AP 
AP occurring in setting of a high serum triglyceride level (>500 mg/dL) with 
exclusion of other causes. Post ERCP AP: development of AP within 24 hours of 
ERCP 
Other cause of AP AP with the presence of a clear inciting factor, such as a suspected medication. 
Idiopathic AP AP not fitting any of the above mentioned categories 
Early pancreatic 
interventions 
Open surgical, minimally invasive, endoscopic, or percutaneous approaches in 
drainage or debridement, performed within 2 weeks of admission 
Organ Failure Score >1 on the modified Marshal system for cardiovascular, pulmonary, or renal 
failure 
Time of admission Time of index presentation to hospital; in cases where subjects were transferred 
from outside hospitals, time of admission referred to the original presentation to the 
hospital, and total LOS included the duration of stay in both the primary and referral 
center 
Enteral nutrition Nutrition by means of a feeding tube (nasogastric or nasojejunal) 
Parenteral nutrition Intravenous nutrition (subjects who received both enteral and parenteral nutrition 
were categorized as having received parenteral nutrition) 




Positive when at least 2 of the following criteria were present:  
1)  Heart rate >90 
2) Body temperature >38 or <36  
3) White blood cell count >12000/mm3 or <4000/ mm3 
4) Respiratory rate >20 
 
























Appendix table 3. Multivariate logistic regression model that compares severity of AP (severe 
AP vs. mild/moderately severe APs) among regions 
Variables OR (95% CI) p-value 
Regions (vs. North 
America) 
 <0.001* 
Europe 11.2 (5.8,21.6) <0.01 
India 7.0 (3.8,12.8) <0.01 
Latin America 5.6 (2.8,11.1) <0.01 
Age 1.0 (1.0,1.0) 0.28 
Gender (Male) 1.9 (1.2,2.8) <0.01 
BMI (>=30) 1.4 (0.9,2.1) 0.13 
Charlson score (>1) 0.7 (0.4,1.3) 0.29 
Etiology (vs. Biliary)  0.045* 
Alcoholic 1.5 (0.9,2.5) 0.11 
Post-ERCP 1.2 (0.5,2.8) 0.67 
Other 1.0 (0.6,1.7) 0.91 
Transfer (Yes) 5.8 (3.7,9.0) <0.01 
Cholecystectomy 
(Yes) 
0.3 (0.1,0.7) <0.01 
Opioid Use (Yes) 5.2 (3.4,8.1) <0.01 
 
*  The likelihood ratio tests were used for the association between severity of AP and factors with more than 2 
categories (region and etiology). 
A backward model selection procedure was followed 
 
Appendix table 4. Multivariable linear regression model that compares length of stay (LOS) 
among regions.  
 
Variable Beta (95% CI) p-value 
Regions (vs. NA)  <0.001* 
EU 4.3 (3.3,-5.4) <0.01 
IND 1.1 (-0.1,-2.3) 0.07 
LA 6.4 (5.2,7.7) <0.01 
Age 0.0 (0.0,0.0) 0.79 
Gender (Male) 0.2 (-0.6,1.1) 0.94 
BMI (>=30) 0.1 (-0.8,1.0) 0.45 
Charlson score (>1) 0.1 (-1.2,1.4) 0.57 
Etiology (vs Biliary)  0.02* 
Alcoholic 0.9 (-0.3,2.2) 0.13 
Post-ERCP 0.1 (-1.4,1.6) 0.87 
Other 0.3 (-0.8,1.3) 0.59 
Transfer (Yes) 2.2 (1.3,3.1) <0.01 
Cholecystectomy 
(Yes) 
4.6 (3.5,5.8) <0.01 
RAC (vs Moderate)  <0.01* 
Mild -5.6 (-6.6,-4.7) <0.01 
Severe 10.6 (9.1,12.0) <0.01 
 
* The likelihood ratio tests were used for the association between LOS of AP and factors with more than 2 
categories (region etiology and severity). 
A backward model selection procedure was followed 
 
 
Appendix table 5. Multivariable logistic regression that compares mortality in patients with 
severe AP among regions. 
Variables OR (95% CI) p-value
Regions (vs NA) <0.001* 
EU 10.4 (2.7,40.5) 0.06 
IND 4.2 (0.9,18.8) <0.01 
LA 8.3 (1.7,41.3) <0.01 
Age 1.0 (1.0,1.1) 0.02 
Gender (Male) 1.4 (0.6,3.4) 0.46 
BMI (>=30) 2.0 (0.8,5.0) 0.13 
Charlson score (>1) 1.2 (0.3,4.5) 0.65 
* The likelihood ratio test was used for the association between mortality of AP and regions.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Acute Pancreatitis Patient Registry To Examine Novel Therapies In 





• Prospective collection of demographic, clinical, laboratory, and radiologic data in 
acute pancreatitis patients from several centers throughout the world with central 
storage of de-identified data at the University of Pittsburgh 
• Evaluation of the existing risks, predictive scores, and markers of severe disease and 
allocation of patients in the two recent severity classifications based on their clinical 
course 




Background and Significance 
 
Acute pancreatitis (AP) is an acute inflammatory process of the pancreas with 
variable clinical course but generally is characterized by sudden onset of upper abdominal 
pain radiating to the back, nausea, epigastric tenderness and elevation of pancreatic 
digestive enzymes ( e.g. amylase and lipase) in the serum and urine. Currently, AP is the 
leading cause of GI related admissions in the US hospitals resulting in high physical and 
financial burden (Gastroenterology 2012;143:1179-87.e1-3). Most cases are mild and self-
limited; however, around 20% of AP cases result in local or systemic complications 
associated with high morbidity and mortality that can reach up to 30% (Gut 2013;62:102-
11). 
 
Over the last 2 decades there has been increased interest in evaluating clinical 
severity of patients with AP.  This research has led to the revision of disease definitions and 
severity classification. Examples of commonly used AP classification systems are Revised 
Atlanta Classification Group (Gut 2013;62:102-11) and the Determinant Based 
Classification (Ann Surg 2012;256: 875–880) systems.  In addition, available clinical scores 
and markers at predicting the severity of AP are only moderately accurate (Mounzer R. 
Gastroenterology 2012).  
 
The management of AP is largely based on expert opinions. Further large 
randomized controlled trials are needed and novel therapeutic approaches are necessary in 
order to provide foundations for determining best course of treatment/s, symptom 
management, and develop novel therapeutic approaches.   
 
V 6.26.2015 
Further challenges may be explained by limitations in current studies in which the 
statistical power is limited because of small patient population and/or because they are 
conducted in a single center. In order to address these issues, we propose a multi-center, 
international, collaboration of major AP centers to develop a network of qualified 
investigators throughout the world and enroll large number of subjects into an online 
database.  The results of this study and development of this database will show the 
feasibility of developing multicenter, international protocols in AP aiming to identify risks 
and improve treatment of AP. 
 
Methods: 
This is a multi-center, prospective study, which will aim to recruit and follow 
hospitalized patients with AP. This study is coordinated by the pancreas group at the 
University of Pittsburgh Medical Center (UPMC) and supported by the Collaborative 
Alliance for Pancreatic Education and Research community (CAPER). The study will include 
adults with confirmed diagnosis of AP admitted to the hospital.  Each center’s research 
team will determine patient’s eligibility to participate in this research study. 
This is an observational study, collecting clinical data in patients with AP. Data 
collection will include: severity of symptoms, pain, demographics, laboratory markers, 
radiologic findings, management, hospital course, and outcomes.  Our primary 
outcome variables are presence of persistent organ failure and pancreatic necrosis as 
those two are the main determinants of severity suggested by the two revised severity 
classifications (Revised Atlanta Classification and Determinant-Based Classification). Based 
on those two main outcomes we will evaluate existing risks, predictive scores, and markers 
of severe disease. Furthermore, we will evaluate current management practices in AP 
patients around the world. Secondary outcomes that will be studied include need for ICU, 
need for nutritional support, need for intervention, hospital length of stay and 
mortality. 
 
De-identified data from each center will be recorded in an online standardized 
questionnaire through the REDCap website. Research coordinators gather data through 
both direct interview and patients’ clinical records. Those variables, which are required to 
be collected through patient interview, are labeled by brackets in the questionnaire. 
Completion of this questionnaire takes, on average, 45 minutes, while patient 
interviews are usually less than 30 minutes. The research coordinator and investigators 
at each center will be provided with a unique password protected username to access 
REDCap.  They will be responsible for verifying patients’ eligibility and data entry.  
The questionnaire is designed to gather information about patient 
demographics, pancreatic disease history, family history, alcohol use, current 
medications, clinical characteristics, diagnostic tests, current therapies, hospital 
course, interventions and disease classification. Patients will be contacted within 30-
90 days after discharge from the hospital to complete a follow-up questionnaire. The 
follow-up questionnaire will mainly focus on recurrent attacks of AP, the need to 
delay intervention, and the potential development of AP-related complications, i.e. 
V 6.26.2015 
diabetes mellitus and exocrine pancreatic insufficiency. 
Recruitment Procedures: 
 
  Recruitment will be accomplished using the Investigators’ and co-investigators’ own 
patient population at each center. Every principal investigator and co-investigator have 
been selected based on their expertise in AP research.  Investigators will correctly 
diagnose the patients with AP and review the inclusion and exclusion criteria 
according to protocol. Eligible patients will be approached by study personnel and the 
study will be explained to them. In the event that the patient is not able to give consent (e.g.  
intubated and unable to talk) the patient’s proxy will complete the consent form. 
Patients who are interested in participating in the study will be given a detailed approved 
consent form that explains the study and informs them of the potential risks and benefits 
associated with participation in the study.  After all of the patients questions and concerns 
are addressed by the study coordinator and/or investigator and the consent form is signed, 
the research coordinator and/or investigator will conduct the interview.  This will occur 
during the patient’s hospital stay.    The participant will then be contacted after 30 to 90 
days post discharge from hospital. 
Power and statistical approach: 
 
We plan to recruit 5,000 cases in one year. For the evaluation of existing predictive 
scores, z- statistic will be utilized for sample size calculation since both predictive scores 
and primary outcomes are dichotomous variables. Continuous data will be evaluated for 
normality of distribution by the Kolmogorov-Smirnov test (or other). Normally distributed 
data will be presented as mean values ± standard deviation (SD), whereas data that are not 
normally distributed as median values with interquartile range (IQR). Differences between 
two groups with continuous data will be assessed using the student-t test for normally 
distributed data and the Mann-Whitney test for non-normal data distributions. 
Comparisons of three or more groups of data will be made using one-way analysis of 
variance (ANOVA) and Kruskal-Wallis (non-parametric ANOVA) tests.  Discrete data will be 
compared by the chi-square or chi-square trend test depending on the number of groups. A 




The racial, gender and ethnic characteristics of the proposed subject population 
reflects the demographics of the approved research center and surrounding communities 






1. The diagnosis of AP based upon presence of two out of the three following criteria: 
V 6.26.2015 
a. Abdominal pain typical to AP 
b. Serum amylase or lipase levels more than three times the upper limit of 
normal  
c. Imaging findings suggestive of AP 
 
2. Willingness to participate in the study and ability to sign informed consent by 




1. Age under 18 years 
2. Unwilling to provide consent by patient or his/her proxy 
3. Presence of pancreatic cancer 
4. Presence of chronic pancreatitis 
5. Occurrence of AP following a multiple trauma episode 
6. Having history of organ transplant 
7. Presence of any cancer which required chemotherapy or radiation therapy in the 
past year. 
Risks and Benefits: 
 
 The possibility that the results of the research study will become generally known is 
rare and occurs in less than 1% (less than 1 out of 100 people). We developed a process, 
which is detailed in the Data Safety and Monitoring section, in order to reduce the chances 
of this from occurring.  
 
There is no direct benefit to the patient for participation in this study. The 
information obtained from this study may lead to greater knowledge of AP. 
 
Data Safety and Monitoring: 
 
All the data will be collected and stored prospectively on an online database (REDCap) 
accessible by study personnel at each center. The data will be de-identified and assigned a 
study code before storage. REDCap is an established secure online software used to access 
the study material (e.g. questioners), enter and save the collected data, and communicate 
with other sites about the latest news regarding the study.  The data will be monitored by 
the data coordinator at the Pittsburgh Coordinating Site.  All data and safety issues will be 
discussed at regularly scheduled DSM meetings with the PI. 2.  The data will be de-
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identified by each site and the link of study code to study code to identity will be 
maintained by each site. No identifying information will be entered into the database. 
Every center will have access to their own data. Raw data from all centers will be 
stored centrally in the REDCap coordinating site at the University of Pittsburgh. The data 
will be accessible by the analysis and publication committee of APPRENTICE with their 
members including Dr. Papachristou (PI) and additional principal investigators from other 
geographical areas. All collaborators will be invited to propose research ideas based on 
their expertise and experience and will have an opportunity to lead one of the projects. The 
committee will be in charge of assigning projects to individual investigators and setting a 
time frame for completion. An experienced statistician at the coordinating or leading center 
based on resources, will have access to the relevant de-identified data so as to complete the 
statistical analysis for each project. 
 
Cost and Compensation: 
 
There are no costs to the participant or the participants insurance for procedures 
conducted for research purposes only. 
 
There is no compensation to those patients participating in this study. 
 
 Qualifications of Investigators: 
 
PI-Georgios Papachristou, M.D., is an Associate Professor at the Division of 
Gastroenterology, Hepatology and Nutrition, University of Pittsburgh. Dr. Papachristou has 
conducted an extensively important researches focused on AP and continues to do research 
and clinical studies on AP.  He has over 100 publications and many federal and foundation 
grants.  
 
David C. Whitcomb, M.D., Ph.D., is a Professor of Medicine in the Division of 
Gastroenterology and Hepatology, Department of Medicine, Cell Biology and Physiology, 
and Human Genetics, University of Pittsburgh, and Chief of the Division of Gastroenterology 
and Hepatology.  
 
Dhiraj Yadav, M.D., is an Associate Professor of Medicine in the Division of 
Gastroenterology, Hepatology and Nutrition, University of Pittsburgh. He is an expert in 
epidemiology and alcoholic pancreatitis.  
 
Amir Gougol, M.D., is a research scholar with the University of Pittsburgh, Department of 
Medicine, Gastroenterology division.   
 
Efstratios Koutroumpakis, M.D., is a research scholar with the University of Pittsburgh, 
Department of Medicine, Gastroenterology division.   
 
Venkata Akshintala, M.D., is a resident of Internal Medicine at UPMC   
 
V 6.26.2015 
Kim Stello is a member of the research staff with the University of Pittsburgh, Department 
of Medicine, Gastroenterology division.   
 
Danielle Dwyer is a member of the research staff with the University of Pittsburgh, 
Department of Medicine, Gastroenterology division.   
Gregory Owens, BA, CCRP is a research coordinator in the Department of Medicine, Division 
of Gastroenterology, University of Pittsburgh 
 
